SCHEMBL7190819

SCHEMBL7190819

COc1ccc(CNC(=O)c2ccc3c(c2)c(=O)n(CC=CC(=O)O)c(=O)n3C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
MMP13 P45452 2/20 0.48
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
RECQL P46063 1/20 0.48
RXFP1 Q9HBX9 2/20 0.47
PPARG P37231 1/20 0.45
TP53 P04637 3/20 0.44
AKR1C3 P42330 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
AKR1C4 P17516 1/20 0.44
AKR1C2 P52895 1/20 0.44
POLB P06746 1/20 0.44
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7190815 1.00 MAPT (0.49) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL7629640 0.93 MAPT (0.49) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL7145385 0.90 MAPT (0.51) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL7103427 0.88 MAPT (0.55) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL7099399 0.87 MAPT (0.50) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL7629654 0.87 MAPT (0.48) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL7629636 0.87 MAPT (0.48) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL7627970 0.86 MAPT (0.52) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL6234634 0.86 MMP13 (0.58) MAPTMMP13KDM4EMEN1KMT2A
SCHEMBL6244546 0.85 ROCK2 (0.47) MAPTMMP13KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MAPT 4823/4885MMP13 1/4885KDM4E 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.